At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ZBIO Zenas BioPharma Inc.
Trading 02-23 11:52:13 EST
25.98
+0.10
+0.39%
High27.50Low25.80Vol187.02K
Open25.98D1 Closing25.88Amplitude6.57%
Mkt Cap1.39BTradable Cap547.45MTotal Shares53.68M
T/O4.93MT/O Rate0.89%Tradable Shares21.07M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Zenas BioPharma Grants Inducement Stock Options and RSUs to New Hires
Reuters  ·  02-21 05:15
Zenas BioPharma Grants Inducement Stock Options and RSUs to New Hires
Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  02-21 05:15
Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  02-21 05:15
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma added to Best Ideas List at Wedbush
TIPRANKS  ·  02-18
Zenas BioPharma added to Best Ideas List at Wedbush
Why Zenas BioPharma (ZBIO) Is Up 17.4% After Positive Phase 2 Obexelimab MS Data And What's Next
Simply Wall St.  ·  02-16
Why Zenas BioPharma (ZBIO) Is Up 17.4% After Positive Phase 2 Obexelimab MS Data And What's Next
Director Patricia L. Allen Reports Acquisition of Zenas Biopharma Common Shares
Reuters  ·  02-14
Director Patricia L. Allen Reports Acquisition of Zenas Biopharma Common Shares
Zenas Biopharma Launches Amended Short-Term Incentive Plan for Employees
Reuters  ·  02-14
Zenas Biopharma Launches Amended Short-Term Incentive Plan for Employees
Evercore ISI Reaffirms Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)
TIPRANKS  ·  02-13
Evercore ISI Reaffirms Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)
Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.
Dow Jones  ·  02-10
Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.
Zenas Biopharma Reports Phase 2 MoonStone Trial Shows Obexelimab Significantly Reduces MS Lesions
Reuters  ·  02-09
Zenas Biopharma Reports Phase 2 MoonStone Trial Shows Obexelimab Significantly Reduces MS Lesions
Zenas Biopharma Announces Late-Breaking Platform Presentation of Results From Phase 2 Moonstone Trial of Obexelimab in Relapsing Multiple Sclerosis at Actrims Forum 2026
THOMSON REUTERS  ·  02-09
Zenas Biopharma Announces Late-Breaking Platform Presentation of Results From Phase 2 Moonstone Trial of Obexelimab in Relapsing Multiple Sclerosis at Actrims Forum 2026
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire  ·  02-04
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
A Big Boss Bet on Zenas BioPharma’s Future
TIPRANKS  ·  02-04
A Big Boss Bet on Zenas BioPharma’s Future
Zenas Biopharma CEO Leon O. Moulder Jr. Reports Acquisition of Common Shares
Reuters  ·  02-04
Zenas Biopharma CEO Leon O. Moulder Jr. Reports Acquisition of Common Shares
Zenas BioPharma Grants Stock Options to New Employee Under Inducement Plan
Reuters  ·  01-17
Zenas BioPharma Grants Stock Options to New Employee Under Inducement Plan
Zenas Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  01-17
Zenas Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  01-17
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zenas Biopharma Unveils Pipeline Strategy Targeting Autoimmune and Multiple Sclerosis Markets
Reuters  ·  01-12
Zenas Biopharma Unveils Pipeline Strategy Targeting Autoimmune and Multiple Sclerosis Markets
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Benzinga_recent_news  ·  01-10
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Zenas Biopharma CEO Leon O. Moulder Jr. Acquires Common Shares
Reuters  ·  01-10
Zenas Biopharma CEO Leon O. Moulder Jr. Acquires Common Shares

Introduction

Company Name.
Zenas BioPharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--